

Special Issue

2nd Edition of Vaccines against Pneumococcal Infection

Message from the Guest Editor

Streptococcus pneumoniae is a significant cause of community-acquired morbidity and mortality in both pediatric and adult populations worldwide. In addition to being an important cause of respiratory infections, including pneumonia and otitis media, it also is a leading cause of sepsis and meningitis. While it has been susceptible to penicillin for many decades, in recent times it has become more resistant to this drug and other beta-lactam antibiotics, necessitating the use of additional classes of antibiotics. I would like to invite and encourage authors to submit their work to this Special Issue. In particular, I would like to welcome manuscripts on the topic of the distribution of pneumococcal capsular polysaccharide serotypes that are prevalent in various geographic locales and the impact of pneumococcal immunization. Submission of articles that review the pathophysiology of pneumococcal infection—particularly those that identify novel targets and/or strategies for next-generation pneumococcal vaccines conferring broad coverage—is also encouraged. Discussions of the novel aspects of the immune responses to these vaccines are also desirable.

Guest Editor

Prof. Dr. Alan Cross

Center for Vaccine Development and Global Health, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA

Deadline for manuscript submissions

closed (25 September 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4

CiteScore 9.9

Indexed in PubMed



mdpi.com/si/139650

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](http://mdpi.com/journal/vaccines)

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

